Trial Profile
Phase II Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer An Investigator-initiated, Single-institution Trial at Magee-Womens Hospital.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2019
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Bevacizumab
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms RADBEV
- 15 Nov 2019 Results published in the Gynecologic Oncology
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 15 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.